Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

This study is using a special type of MRI scan called hyperpolarized carbon-13 pyruvate MRI to monitor how prostate cancer responds to hormone therapy (abiraterone) given before surgery. The goal is to find a better way to predict treatment success without waiting for surgery. **You may be eligible if...** - You are 18 or older - You have confirmed high-risk prostate cancer (high Gleason grade, lymph node involvement, or advanced stage) - You are planning to have surgery to remove your prostate - You have not received previous prostate cancer treatment - Your organ function meets required thresholds **You may NOT be eligible if...** - You cannot have an MRI (e.g., you have a pacemaker or certain metal implants) - You are allergic to gadolinium contrast dye used in MRI - You have poorly controlled high blood pressure or significant heart disease - You are currently on certain medications that interfere with the study drug Talk to your doctor to see if this trial is right for you.